Evidence map›Paper›PMID 23415633›Full record

ArticleNeuropharmacology2013

PPARγ activation blocks development and reduces established neuropathic pain in rats.

J Morgenweck, R B Griggs, R R Donahue, J E Zadina, B K Taylor

Open access · greenAbstract read
In one paragraph

Article in Neuropharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. The Cannabidiol Analog PECS-101 Prevents Chemotherapy-Induced Neuropathic Pain via PPARγ Receptors.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. PPARs and pain.British journal of pharmacology · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

J MorgenweckDepartment of Physiology, University of Kentucky Research Foundation, Lexington, KY 40536, USA.
R B Griggs
R R Donahue
J E Zadina
B K Taylor
University of Kentucky · USTulane University · US

Funding

PPAR Inhibition of Spinal Pain TransmissionR01NS062306 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TAYLOR, BRADLEY K. · 2009 to 2021
$4.0M
Neuropeptidergic Inhibition of Spinal Pain TransmissionK02DA019656 · NIDA · UNIVERSITY OF KENTUCKY · PI TAYLOR, BRADLEY K. · 2007 to 2011
$574k
NIDA NIH HHS 5K02DA19656NIDA NIH HHS K02 DA019656NINDS NIH HHS 5R01NS62306NINDS NIH HHS R01 NS062306
6 · The paper itself

Abstract

Peroxisome proliferator-activated receptor gamma (PPARγ) is emerging as a new pharmacotherapeutic target for chronic pain. When oral (3-30 mg/kg/day in chow for 7 wk) or twice-daily intraperitoneal (1-10 mg/kg/day for 2 wk) administration began before spared nerve injury (SNI), pioglitazone, a PPARγ agonist, dose-dependently prevented multiple behavioral signs of somatosensory hypersensitivity. The highest dose of intraperitoneal pioglitazone did not produce ataxia or reductions in transient mechanical and heat nociception, indicating that inhibitory effects on hypersensitivity were not secondary to adverse drug-induced behaviors or antinociception. Inhibitory effects on hypersensitivity persisted at least one week beyond cessation of pioglitazone administration, suggestive of long-lasting effects on gene expression. Blockade of PPARγ with GW9662, an irreversible and selective PPARγ antagonist, dose-dependently reduced the inhibitory effect of pioglitazone on hypersensitivity, indicating a PPARγ-dependent action. Remarkably, a single preemptive injection of pioglitazone 15 min before SNI attenuated hypersensitivity for at least 2 weeks; this was enhanced with a second injection delivered 12 h after SNI. Pioglitazone injections beginning after SNI also reduced hypersensitivity, albeit to a lesser degree than preemptive treatment. Intraperitoneal pioglitazone significantly reduced the nerve injury-induced up-regulation of cd11b, GFAP, and p-p38 in the dorsal horn, indicating a mechanism of action involving spinal microglia and/or astrocyte activation. Oral pioglitazone significantly reduced touch stimulus-evoked phospho-extracellular signal-related kinase (p-ERK) in lamina I-II, indicating a mechanism of action involving inhibition of central sensitization. We conclude that pioglitazone reduces spinal glial and stimulus-evoked p-ERK activation and that PPARγ activation blocks the development of and reduces established neuropathic pain.

Indexed as

AnilidesAnimalsAtaxiaCD11b AntigenDose-Response Relationship, DrugDrug Administration ScheduleExtracellular Signal-Regulated MAP KinasesGlial Fibrillary Acidic ProteinHyperalgesiaMaleNeuralgiap38 Mitogen-Activated Protein KinasesPioglitazonePosterior Horn CellsPPAR gammaRats2-chloro-5-nitrobenzanilideAnilidesCD11b AntigenExtracellular Signal-Regulated MAP KinasesGlial Fibrillary Acidic Proteinp38 Mitogen-Activated Protein KinasesPioglitazonePPAR gammaThiazolidinediones

Identifiers

PMID23415633
PMCPMC3695821
OpenAlexW1985719155

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.